116 related articles for article (PubMed ID: 20046704)
1. 3D-QSAR CoMFA study of some Heteroarylpyrroles as Possible Anticandida Agents.
Sharma PC; Sharma SV; Sharma A; Suresh B
Indian J Pharm Sci; 2008; 70(2):154-8. PubMed ID: 20046704
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: A comparative molecular field analysis study.
Kulkarni SS; Kulkarni VM
J Med Chem; 1999 Feb; 42(3):373-80. PubMed ID: 9986707
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach.
Zhang Z; An L; Hu W; Xiang Y
J Comput Aided Mol Des; 2007 Apr; 21(4):145-53. PubMed ID: 17203365
[TBL] [Abstract][Full Text] [Related]
6. CoMFA and CoMSIA 3D-QSAR analysis of DMDP derivatives as anti-cancer agents.
Srivastava V; Kumar A; Mishra BN; Siddiqi MI
Bioinformation; 2008 Jun; 2(9):384-91. PubMed ID: 18795111
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure activity relationship (QSAR) of cytotoxic active 3,5-diaryl-4,5-dihydropyrazole analogs: a comparative molecular field analysis (CoMFA) revisited study.
Hamad Elgazwy AS; Soliman DS; Atta-Allah SR; Ibrahim DA
Chem Cent J; 2012 May; 6(1):50. PubMed ID: 22647291
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.
Jiang YK
J Mol Model; 2010 Jul; 16(7):1239-49. PubMed ID: 20069322
[TBL] [Abstract][Full Text] [Related]
11. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
[TBL] [Abstract][Full Text] [Related]
12. Modification of polychlorinated phenols and evaluation of their toxicity, biodegradation and bioconcentration using three-dimensional quantitative structure-activity relationship models.
Tong L; Guo L; Lv X; Li Y
J Mol Graph Model; 2017 Jan; 71():1-12. PubMed ID: 27825025
[TBL] [Abstract][Full Text] [Related]
13. Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
Horwitz JP; Massova I; Wiese TE; Wozniak AJ; Corbett TH; Sebolt-Leopold JS; Capps DB; Leopold WR
J Med Chem; 1993 Nov; 36(23):3511-6. PubMed ID: 8280289
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
[TBL] [Abstract][Full Text] [Related]
15. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA.
Pirhadi S; Ghasemi JB
Eur J Med Chem; 2010 Nov; 45(11):4897-903. PubMed ID: 20810190
[TBL] [Abstract][Full Text] [Related]
18. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
Shagufta ; Kumar A; Panda G; Siddiqi MI
J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
[TBL] [Abstract][Full Text] [Related]
19. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
Dowlati Beirami A; Hajimahdi Z; Zarghi A
J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
[TBL] [Abstract][Full Text] [Related]
20. Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors.
Murumkar PR; Gupta SD; Zambre VP; Giridhar R; Yadav MR
Chem Biol Drug Des; 2009 Jan; 73(1):97-107. PubMed ID: 19152638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
